The combination of PABPC1 expression and regimen revealed that paclitaxel-based IC + CCRT is a better regimen for patients with PABPC1 low expression than the other regimens, suggesting that PABPC1 could potentially triage NPC patients and enhance personalized treatment. This evidence concerns the gene PABPC1 and nasopharyngeal carcinoma.